Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
brief summary
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery. It is intended for men with high-risk localized or locally advanced prostate cancer who have no distant spread on imaging and are suitable for surgery. The researchers will measure how often treatment leaves no cancer or only a very small amount of cancer in the prostate, with no cancer in the pelvic lymph nodes removed during surgery. They will also assess whether participants can undergo the planned surgery, what side effects occur, and whether the cancer returns or spreads during follow-up. Up to 37 participants will be enrolled at several hospitals. All participants will be assigned to the same treatment plan; there is no comparison group. The planned treatment includes: * Deutenzalutamide taken by mouth each day, together with hormone therapy to lower testosterone levels, for 24 weeks before surgery. * Docetaxel given through a vein once every 3 weeks for six cycles during the treatment period before surgery. * Surgery to remove the prostate and pelvic lymph nodes, when medically appropriate. * A further 24 weeks of deutenzalutamide and hormone therapy after recovery from surgery, without further docetaxel. Hormone therapy will continue across the treatment periods for a total of at least 13 months. Treatment may be adjusted or stopped according to side effects and the participant's condition. Follow-up is planned for up to 5 years after all study treatment has ended. Participants may also choose to join an optional study using a single blood sample collected before treatment and leftover tissue from their diagnostic prostate biopsy. These samples will be used to explore features that may be associated with treatment response and later outcomes. Participation in this optional component is not required to receive the study treatment.
detailed description
POST-PC-01 is an investigator-initiated, prospective, multicenter, single-arm, open-label exploratory study. The rationale is to combine androgen receptor pathway inhibition and androgen deprivation with chemotherapy before definitive surgery, while limiting docetaxel exposure to the preoperative period. The study will generate preliminary evidence on antitumor activity, safety, and clinical feasibility; it is not designed to establish superiority over another treatment.
The study uses a Simon minimax two-stage design. The first stage includes 16 participants in the prespecified primary efficacy decision analysis set. Enrollment will proceed to the second stage only if the first-stage results meet the predefined continuation criterion. The second stage adds 15 participants, for a total of 31 participants in the decision analysis set. The maximum enrollment of 37 allows limited replacement under protocol-defined circumstances unrelated to treatment efficacy or tolerability. Participants unable to undergo surgery because of disease progression or treatment toxicity are counted as nonresponders rather than replaced.
The optional exploratory component is limited to pretreatment samples. It includes one peripheral blood collection of 20 mL for genetic analysis and the use of residual tissue from the diagnostic prostate biopsy. Tissue assessments include intraductal carcinoma of the prostate, BRCA1 and BRCA2 and other DNA repair-related gene alterations, and PTEN deletion or related abnormalities. No additional biopsy is performed for this component.
Where samples and outcome data are available, associations between baseline pathological or genetic features and pathological response, recurrence, or progression will be explored descriptively. Participation requires an affirmative choice within the study informed consent form. Declining or withdrawing from this optional component does not affect participation in the study treatment and follow-up.
official title
POST-PC-01: A Prospective, Multicenter, Single-Arm, Open-Label, Exploratory Study of Perioperative Deutenzalutamide Plus Androgen-Deprivation Therapy With the Addition of Docetaxel in the Neoadjuvant Phase in Patients With High-Risk Localized or Locally Advanced Prostate Cancer